Cite
HARVARD Citation
Blauvelt, A. et al. (2022). Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. Journal of dermatological treatment. pp. 2605-2613. [Online].